home / stock / lian / lian news

LIAN News and Press, LianBio From 08/03/23

Stock Information
Company Name: LianBio
Stock Symbol: LIAN
Market: NASDAQ
Menu
LIAN LIAN Quote LIAN Short LIAN News LIAN Articles LIAN Message Board
Get LIAN Alerts

News, Short Squeeze, Breakout and More Instantly...
LIAN - LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial...
LIAN - Tarsus granted FDA nod for lead asset

2023-07-26 08:50:00 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) announced Tuesday that the FDA greenlighted its lead asset TP-03 as a treatment for the eyelid disorder Demodex blepharitis. Demodex blepharitis affects approximately 25M eyecare patients in the U.S., with a prevalen...

LIAN - LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY(TM) (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner ophthalmic solution) 0.25% for the treatment of...

LIAN - Nanobiotix partners with J&J's Janssen for radiotherapy treatment

2023-07-18 10:26:11 ET LianBio ( NASDAQ: LIAN ) partner Nanobiotix has inked a deal with Johnson & Johnson ( NYSE: JNJ ) division Janssen Pharmaceutica on the development of radioenhancer NBTXR3. Janssen is receiving a worldwide license for co-development and comme...
LIAN - LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

SHANGHAI, China and PRINCETON, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that partner Nanobiotix has entered into a license agreement w...

LIAN - LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

SHANGHAI, China and PRINCETON, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chine...

LIAN - LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a clinical supply agreement with AstraZeneca in China to evalu...
LIAN - LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS ® (mavacamten) has received marketing approval...

LIAN - LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

•  LIBRA trial designed to support registration of TP-03 in China •  Topline results expected in the fourth quarter of 2023 SHANGHAI, China and PRINCETON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bring...

LIAN - SFIX, WGS and ZUMZ are among after hour movers

2023-06-06 17:21:13 ET Gainers: GeneDx Holdings ( WGS ) +6% . Zumiez ( ZUMZ ) +6% . Stitch Fix ( SFIX ) +6% . LianBio ( LIAN ) +5% . Dave & Buster's Entertainment ( PLAY ) +5% . Losers: Couchbase ( BASE ) -17% ...
Previous 10 Next 10